CN101679347B - 作为hsp90抑制剂的稠和的氨基吡啶 - Google Patents

作为hsp90抑制剂的稠和的氨基吡啶 Download PDF

Info

Publication number
CN101679347B
CN101679347B CN200880016525.7A CN200880016525A CN101679347B CN 101679347 B CN101679347 B CN 101679347B CN 200880016525 A CN200880016525 A CN 200880016525A CN 101679347 B CN101679347 B CN 101679347B
Authority
CN
China
Prior art keywords
compound
mmol
alkyl
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880016525.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679347A (zh
Inventor
蔡雄
钱长庚
翟海啸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of CN101679347A publication Critical patent/CN101679347A/zh
Application granted granted Critical
Publication of CN101679347B publication Critical patent/CN101679347B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880016525.7A 2007-03-20 2008-03-10 作为hsp90抑制剂的稠和的氨基吡啶 Active CN101679347B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89592107P 2007-03-20 2007-03-20
US60/895,921 2007-03-20
US1528807P 2007-12-20 2007-12-20
US61/015,288 2007-12-20
PCT/US2008/056396 WO2008115719A1 (en) 2007-03-20 2008-03-10 Fused amino pyridine as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
CN101679347A CN101679347A (zh) 2010-03-24
CN101679347B true CN101679347B (zh) 2014-10-22

Family

ID=39766345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880016525.7A Active CN101679347B (zh) 2007-03-20 2008-03-10 作为hsp90抑制剂的稠和的氨基吡啶

Country Status (24)

Country Link
US (10) US8324240B2 (OSRAM)
EP (1) EP2069324B1 (OSRAM)
JP (1) JP5401329B2 (OSRAM)
KR (1) KR101313804B1 (OSRAM)
CN (1) CN101679347B (OSRAM)
AU (1) AU2008229216B2 (OSRAM)
BR (1) BRPI0808301B1 (OSRAM)
CA (1) CA2680778C (OSRAM)
CY (1) CY1114507T1 (OSRAM)
DK (1) DK2069324T3 (OSRAM)
EA (1) EA019103B1 (OSRAM)
ES (1) ES2430217T3 (OSRAM)
HR (1) HRP20130910T1 (OSRAM)
IL (2) IL200924A (OSRAM)
MX (1) MX2009009936A (OSRAM)
MY (1) MY148860A (OSRAM)
NZ (1) NZ579635A (OSRAM)
PL (1) PL2069324T3 (OSRAM)
PT (1) PT2069324E (OSRAM)
RS (1) RS52978B (OSRAM)
SI (1) SI2069324T1 (OSRAM)
TW (1) TWI471131B (OSRAM)
WO (1) WO2008115719A1 (OSRAM)
ZA (1) ZA200906371B (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) * 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
EP2088500A1 (en) 2008-02-11 2009-08-12 Idean Enterprises Oy Layer based user interface
US8017780B1 (en) 2008-10-09 2011-09-13 Myrexis, Inc. Therapeutic compounds and uses thereof
WO2010083403A1 (en) 2009-01-16 2010-07-22 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
MY152972A (en) * 2009-07-10 2014-12-15 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
KR101906568B1 (ko) * 2009-10-07 2018-10-10 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
WO2012131413A1 (en) 2011-03-25 2012-10-04 Debiopharm Sa Crystalline forms of fused amino pyridines as hsp90 inhibitors
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
ES2647889T3 (es) * 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
JP6289362B2 (ja) * 2011-04-26 2018-03-07 アールディーディー ファーマ リミテッド 肛門直腸疾患の処置のためのオキシメタゾリン
CN107474085B (zh) 2012-02-09 2021-05-11 堪萨斯大学 Hsp90 C端抑制剂及其医药组合物和用途
HK1209035A1 (en) 2012-05-25 2016-03-24 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
EP3152307A4 (en) 2014-06-06 2018-05-02 Berg LLC Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
WO2015200514A2 (en) 2014-06-24 2015-12-30 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
JP6594570B2 (ja) 2017-03-20 2019-10-23 フォーマ セラピューティクス，インコーポレイテッド ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物
EP3600376A1 (en) * 2017-03-31 2020-02-05 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
CN112513058B (zh) 2018-05-14 2024-08-20 里亚塔医药公司 治疗与热休克蛋白通路有关的疾病的具有修饰糖基团的联芳基酰胺类
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
AU2023356671A1 (en) * 2022-10-06 2025-04-24 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025014551A1 (en) * 2023-07-10 2025-01-16 Regranion, Llc Methods and compositions for treating atopic dermatitis
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080629A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating behçet's disease
WO2025080645A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating bullous pemphigoid
WO2025080623A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217284A1 (en) * 2024-04-09 2025-10-16 Regranion, Llc Methods and compositions for treating inflammatory and autoimmune disorders of the skin
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002597A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
CN1365361A (zh) * 1999-07-02 2002-08-21 卫材株式会社 缩合咪唑化合物和治疗糖尿病的药物
CN1525974A (zh) * 2001-07-31 2004-09-01 ϣ��������ҩ��ҵ��˾ 用作腺苷A2a受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006114180A1 (de) * 2005-04-25 2006-11-02 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
EA200000768A1 (ru) * 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
EP1058549A4 (en) * 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
JP4829449B2 (ja) * 1999-07-28 2011-12-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 置換オキソアザヘテロシクリル化合物
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
EP1335920B1 (en) 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Compositions containing purine derivatives for binding to hsp90
AU2002343604C1 (en) * 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
WO2004072080A1 (en) * 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
EP1784180A4 (en) 2004-09-02 2009-07-22 3M Innovative Properties Co 2-AMINO-1H-IMIDAZO RING SYSTEMS AND METHOD
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2007075572A2 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
NZ572600A (en) * 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
PL2343286T3 (pl) 2006-10-28 2015-06-30 Methylgene Inc Pochodne dibenzo[b,f][1,4]oksazepiny jako inhibitory deacetylazy histonowej
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
WO2010083403A1 (en) 2009-01-16 2010-07-22 Curis, Inc. Fused amino pyridines for the treatment of brain tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002597A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
CN1365361A (zh) * 1999-07-02 2002-08-21 卫材株式会社 缩合咪唑化合物和治疗糖尿病的药物
CN1525974A (zh) * 2001-07-31 2004-09-01 ϣ��������ҩ��ҵ��˾ 用作腺苷A2a受体的配体的三唑基－咪唑并吡啶和三唑基嘌呤类的衍生物及其作为药物的应用
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006114180A1 (de) * 2005-04-25 2006-11-02 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Huiyong Hu e al..Potent 4-amino-5-azaindole factor VIIa inhibitors.《Bioorganic & Medicinal Chemistry Letters》.2006,第16卷第4567–4570页. *
Patrizia Minetti et al..2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and Analogues as A2A Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization.《J. Med. Chem.》.2005,第48卷(第22期),第6887-6896页. *
Paul Barraclough et al..Inotropic A Ring Substituted Sulmazole and Isomazole Analogues.《J. Med. Chem.》.1990,第33卷(第8期),第2231-2239页. *
Rodney C. Young et al..Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatidylinositol 4-Kinase.《J. Med. Chem.》.1990,第33卷(第8期),第2073-2080页. *

Also Published As

Publication number Publication date
US20120237508A1 (en) 2012-09-20
KR20100015739A (ko) 2010-02-12
US20160058742A1 (en) 2016-03-03
RS52978B (sr) 2014-02-28
JP5401329B2 (ja) 2014-01-29
WO2008115719A1 (en) 2008-09-25
EP2069324B1 (en) 2013-07-31
CN101679347A (zh) 2010-03-24
US20140221343A1 (en) 2014-08-07
CA2680778A1 (en) 2008-09-25
TWI471131B (zh) 2015-02-01
IL200924A (en) 2015-02-26
US9630965B2 (en) 2017-04-25
EA019103B1 (ru) 2014-01-30
AU2008229216B2 (en) 2013-03-21
MX2009009936A (es) 2010-02-11
US10844056B2 (en) 2020-11-24
HRP20130910T1 (hr) 2013-10-25
US10035797B2 (en) 2018-07-31
PT2069324E (pt) 2013-10-10
US20200062754A1 (en) 2020-02-27
AU2008229216A1 (en) 2008-09-25
ZA200906371B (en) 2010-05-26
IL236938A0 (en) 2015-03-31
CA2680778C (en) 2016-05-10
US20190010152A1 (en) 2019-01-10
US20170267674A1 (en) 2017-09-21
US10428068B2 (en) 2019-10-01
WO2008115719A9 (en) 2009-02-26
US11560377B2 (en) 2023-01-24
US8586605B2 (en) 2013-11-19
DK2069324T3 (da) 2013-09-02
KR101313804B1 (ko) 2013-10-01
US20170002002A1 (en) 2017-01-05
HK1131986A1 (en) 2010-02-12
BRPI0808301A2 (pt) 2013-08-06
CY1114507T1 (el) 2016-10-05
EP2069324A1 (en) 2009-06-17
BRPI0808301B1 (pt) 2022-05-03
ES2430217T3 (es) 2013-11-19
TW200845967A (en) 2008-12-01
JP2010522184A (ja) 2010-07-01
SI2069324T1 (sl) 2013-10-30
US20210292317A1 (en) 2021-09-23
US8324240B2 (en) 2012-12-04
EP2069324A4 (en) 2011-09-07
US20080234314A1 (en) 2008-09-25
MY148860A (en) 2013-06-14
PL2069324T3 (pl) 2014-01-31
EA200901263A1 (ru) 2010-02-26
IL200924A0 (en) 2010-05-17
US9402832B2 (en) 2016-08-02
US9040556B2 (en) 2015-05-26
NZ579635A (en) 2011-07-29
US20230192687A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CN101679347B (zh) 作为hsp90抑制剂的稠和的氨基吡啶
TWI423971B (zh) 含鋅結合位之酪胺酸激酶抑制劑
CN101674833A (zh) 含有锌结合半族的Raf激酶抑制剂
EP3383877B1 (en) Heterocycle compounds and uses thereof
CA2786715C (en) Fused amino pyridines for the treatment of brain tumors
HK1131986B (en) Fused amino pyridine as hsp90 inhibitors
HK1142602A (en) Fused amino pyridine as hsp90 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142602

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142602

Country of ref document: HK